TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00398905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 5 mg twice daily (10 mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 10 mg twice daily (20 mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 20 mg twice daily (40 mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 30 mg twice daily (60 mg total daily dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg once daily (40 mg total daily dose)
Study: NCT02616952

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese herbal therapy
Description: Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
Study: NCT04426851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: BI 1358894
Study: NCT02951858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The participants only receive the materials about the harm of substance use.
Study: NCT03090880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin Sodium
Description: Subcutaneous tinzaparin 4,500 IU once daily for six months.
Study: NCT00871858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given intramuscularly
Study: NCT02616952

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pelvic floor muscle training
Description: In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
Study: NCT01366963

Intervention type: BEHAVIORAL
Intervention: Seated Measurements
Description: The following measurements will take place in a seated position:~Ruff 1 \& 7 (visual search and attention processes) Trails A \& B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)

Intervention type: BEHAVIORAL
Intervention: Seated Measurements
Description: The following measurements will take place in a seated position:~Ruff 1 \& 7 (visual search and attention processes) Trails A \& B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)

Intervention type: BEHAVIORAL
Intervention: Standing Measurements
Description: The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test
Study: NCT01391494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in adults
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in adults
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in adults
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in 12 adults
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in adults
Description: 0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in children
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in children
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in children
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in children
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in children
Description: 0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in infants
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
Study: NCT01366963

Intervention type: BEHAVIORAL
Intervention: Standing Measurements
Description: The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test
Study: NCT01391494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in infants
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in infants
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in infants
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in infants
Description: 0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
Study: NCT01366963

Intervention type: BEHAVIORAL
Intervention: Self-Administered Surveys
Description: Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)

Intervention type: BEHAVIORAL
Intervention: Self-Administered Surveys
Description: Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
Study: NCT01283620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified constraint induced movement therapy (mCIMT)
Description: The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual and Customary Care
Description: Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
Study: NCT03428880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: spinal morphine is done before cesarean section
Study: NCT00429455

Intervention type: BEHAVIORAL
Intervention: Survey
Description: 3-Part Questionnaire
Study: NCT01112267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl/acetaminophen Extended Release
Description: Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl/acetaminophen Extended Release
Description: Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
Study: NCT00212355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-02
Description: zinc acetate
Study: NCT01229670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: * 1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~* 2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: * 1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~* 2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min
Study: NCT03886077

Intervention type: DRUG
Intervention: glecaprevir/pibrentasivir
Description: 12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
Study: NCT01065480

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live teleconference supervision
Description: Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
Study: NCT03428880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: a US Block QLB is done after surgery
Study: NCT01065480

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Taped Review Supervision
Description: Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
Study: NCT01442558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
Study: NCT04420754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIC100 CAR T Cells
Description: Autologous CAR T cells directed against ICAM-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIC100 CAR T Cells
Description: Autologous CAR T cells directed against ICAM-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIC100 CAR T Cells
Description: Autologous CAR T cells directed against ICAM-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIC100 CAR T Cells
Description: Autologous CAR T cells directed against ICAM-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIC100 CAR T Cells
Description: Autologous CAR T cells directed against ICAM-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIC100 CAR T Cells
Description: Autologous CAR T cells directed against ICAM-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIC100 CAR T Cells
Description: Autologous CAR T cells directed against ICAM-1
Study: NCT04308473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra-processed Food Meal
Description: An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra-processed Food Meal
Description: An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Food Meal
Description: A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Food Meal
Description: A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.
Study: NCT01261468

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active SCS
Description: SCS IPG activated

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deactivated
Description: SCS IPG deactivated
Study: NCT03254615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Prefer Plain Water
Description: The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Prefer Plain Water
Description: The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Prefer Plain Water
Description: The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.
Study: NCT02225054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 15 ml 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 15 ml 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 15 ml 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 1 mL 0.9%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1 mL 0.9%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 1 mL 0.9%
Study: NCT04415970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flotation therapy sensory deprivation tank
Description: Participants will float for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with sleep pod every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short safety questionnaire and an anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Pod
Description: Participants will utilize the sleep pod for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with float every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
Study: NCT01915329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RSS (repetitive sensory stimulation)
Description: RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.~In case of the sham-stimulation no pulses are transmitted.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM-RSS
Description: The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
Study: NCT01072565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG to guide clinical decisions
Description: The investigator will base clinical decisions on A1c and modal day analysis of SMBG.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG and CGM
Description: The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
Study: NCT01993836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia with propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with isoflurane
Study: NCT04707547

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: immunotherapy with Nivolumab
Description: After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.
Study: NCT01528540

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will include placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidant plus Pregabalin
Description: This group will contain combination of antioxidant cocktail and pregabalin
Study: NCT03707587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
Study: NCT00540423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-497115-GR 12.5mg
Description: SB-497115-GR 12.5mg tablet once a day
Study: NCT03857347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation Group for FND
Description: he intervention is a psychoeducation based group.
Study: NCT00672113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalat (Nifedipine, BAYA1040)
Description: Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coracten
Description: Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
Study: NCT04057989

Intervention type: DRUG
Intervention: ketamine